In order to compare NGS with conventional methodologies under theoretical conditions, we calculated the turnaround time and cost for three mandatory testing genes in NSCLC (EGFR, ALK and ROS1) and mCRC (KRAS, NRAS and BRAF). This evidence concerns the gene KRAS and non-small cell lung carcinoma.